167 related articles for article (PubMed ID: 12370515)
1. Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
Parienti JJ
AIDS; 2002 Oct; 16(15):2097; author reply 2098. PubMed ID: 12370515
[No Abstract] [Full Text] [Related]
2. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
[No Abstract] [Full Text] [Related]
3. Antiretroviral rounds. When success is a pain.
Bartlett JG; del Rio C
AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
[No Abstract] [Full Text] [Related]
4. Four new antiretroviral medications will soon offer more options to HIV patients.
Murphy MJ
Fac Notes (New Orleans La); 1998; 10(4):1-3. PubMed ID: 11365545
[TBL] [Abstract][Full Text] [Related]
5. [HIV infections: mortality reduced only in developed countries].
Wehr A
Dtsch Med Wochenschr; 1999 May; 124(18):A8-9. PubMed ID: 10356577
[No Abstract] [Full Text] [Related]
6. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
7. Don't mix Sustiva with Fortovase.
Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
[No Abstract] [Full Text] [Related]
9. What's new and what's next.
Fakuda D
Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
[TBL] [Abstract][Full Text] [Related]
10. Two protease inhibitor switch studies show longer virologic response in patients switching to a regimen containing Sustiva.
J Assoc Nurses AIDS Care; 2002; 13(2):88-9. PubMed ID: 11936071
[No Abstract] [Full Text] [Related]
11. Efavirenz therapy in drug users.
Clarke SM; Mulcahy FM
HIV Med; 2000; 1 Suppl 1():15-7. PubMed ID: 11737363
[No Abstract] [Full Text] [Related]
12. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Duval X
Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407
[No Abstract] [Full Text] [Related]
13. Some competition for 1592.
GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
[TBL] [Abstract][Full Text] [Related]
14. Once-daily nonnucleoside reverse-transcriptase inhibitor approved.
Am J Health Syst Pharm; 1998 Dec; 55(23):2458. PubMed ID: 9853628
[No Abstract] [Full Text] [Related]
15. Substitution for protease inhibitors in HIV therapy.
Hirschel B
N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14681514
[No Abstract] [Full Text] [Related]
16. Experience with efavirenz in end-stage renal disease.
Das S; Ghanem M; Huengsberg M
Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
[No Abstract] [Full Text] [Related]
17. Sustiva added to three-drug combination.
AIDS Patient Care STDS; 1998 Oct; 12(10):803. PubMed ID: 11362030
[No Abstract] [Full Text] [Related]
18. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
[No Abstract] [Full Text] [Related]
19. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Molina JM; Journot V; Morand-Joubert L; Yéni P; Rozenbaum W; Rancinan C; Fournier S; Morlat P; Palmer P; Dupont B; Goujard C; Dellamonica P; Collin F; Poizot-Martin I; Chene G;
J Infect Dis; 2005 Mar; 191(6):830-9. PubMed ID: 15717256
[TBL] [Abstract][Full Text] [Related]
20. Four-drug regimens may be better.
AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
[No Abstract] [Full Text] [Related]
[Next] [New Search]
